Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
08 Maggio 2024 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that it will present
information on the preclinical profile of STAR-0310 at the upcoming
Society for Investigative Dermatology (SID) Annual Meeting in
Dallas, Texas on May 16, 2024.
Dr. Chunxia Lily Zhao, Director of Antibody Discovery at Astria
Therapeutics, will present a poster titled, “Preclinical Profile of
STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody” at
Session One of the Pharmacology and Therapeutic Development Select
E-Poster Discussions on May 16, 2024, at 5:00pm CDT.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240508669745/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Gen 2024 a Gen 2025
